These findings suggest that combination therapy targeting the NF-κB pathway can enhance the effect of radiotherapy and reduce the damage to normal tissue, providing a new idea for the treatment of osteosarcoma (Table 2). The gene discussed is NFKB1; the disease is osteosarcoma.